Systemtherapie des Peniskarzinoms – neue Konzepte? Neue Erfolge?

Zusammenfassung

Die systemische Chemotherapie wird seit Jahren mit beim metastasierten Peniskarzinom angewandt, jedoch nur mit begrenztem Erfolg. Ihre Bedeutung liegt überwiegend im Rahmen der multimodalen Therapie bei lymphogener Metastasierung in Zusammenhang mit radikaler Lymphknotenchirurgie. Bei begrenztem Lymphknotenbefall kann die Kombination von operativer Therapie mit cisplatin- und taxanhaltigen Dreifachkombinationen kurativ sein.

Fortschritte im Verständnis der molekularen Veränderungen beim Peniskarzinom und die Suche nach potenziellen Therapietargets haben zur Auflegung zahlreicher Studien geführt. Trotz Hinweisen auf die Wirksamkeit von Immuntherapeutika haben sich bislang jedoch keine wesentlichen therapeutischen Verbesserungen für die klinische Praxis ergeben.

Abstract

Systemic chemotherapy has been in use for metastatic penile carcinoma for years, but its success is limited. Its significance is largely associated with its role in multimodal treatment for lymphatic metastasis in the context of radical lymph node surgery. In cases of limited lymph node involvement, the combination of surgical treatment plus cisplatin- and taxane-based triple combinations may be curative.

Advances in the understanding of molecular changes in penile cancer and the search for potential therapy targets have led to numerous studies. Although there is evidence of efficacy of immunotherapeutics, no significant therapeutic improvements have been seen in the clinical routine.

Schlüsselwörter

Peniskarzinom - Metastasen - Chemotherapie - Immuntherapie - Radiochemotherapie

Keywords

penile cancer - metastasis - chemotherapy - radiochemotherapy - immunotherapy

Publication History

Received: 03 May 2023

Accepted: 24 May 2023

Article published online:
04 August 2023

• Literatur

• 1 Zargar-Shoshtari K, Spiess PE, Berglund AE. et al. Clinical Significance of p53 and p16(ink4a) Status in a Contemporary North American Penile Carcinoma Cohort. Clin Genitourin Cancer 2016; 14: 346-351
• 2 Feber A, Arya M, deWinter P. et al. Epigenetics markers of metastasis and HPV-induced tumorigenesis in penile cancer. Clin Cancer Res 2015; 21: 1196-1206
• 3 Chahoud J, Gleber-Netto FO, McCormick BZ. et al. Whole Exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 2021; 27: 2560-2570
• 4 Chahoud J, Tamil M, Necchi A. Second line salvage systemic therapy for advanced penile cancer. Urol Oncol 2022; 40: 229-234
• 5 Ali SM, Pal SK, Wang K. et al. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. Oncologist 2016; 21: 33-39
• 6 Feber A, Worth DC, Chakravarthy A. et al. CSN1 Somatic Mutations in Penile Squamous Cell Carcinoma. Cancer Res 2016; 76: 4720-4727
• 7 Ottenhof SR, Djajadiningrat RS, Thygesen HH. et al. The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma. Front Immunol 2018; 9: 1253
• 8 Garnick MB, Skarin AT, Steele GD. Metastatic carcinoma of the penis: complete remission after high dose methotrexate chemotherapy. J Urol 1979; 122: 265-266
• 9 Ahmed T, Sklaroff R, Yagoda A. Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer. J Urol 1984; 132: 465-468
• 10 Gagliano RG, Blumenstein BA, Crawford ED. et al. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol 1989; 141: 66-67
• 11 Ahmed T, Sklaroff R, Yagoda A. An appraisal of the efficacy of bleomycin in epidermoid carcinoma of the penis. Anticancer Res 1984; 4: 289-292
• 12 Maiche AG. Adjuvant treatment using bleomycin in squamous cell carcinoma of penis: study of 19 cases. Br J Urol 1983; 55: 542-544
• 13 Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer 1990; 65: 433-438
• 14 Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol 1992; 147: 630-632
• 15 Theodore C, Skoneczna I, Bodrogi I. et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol 2008; 19: 1304-1307
• 16 Kattan J, Culine S, Droz JP. et al. Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy. Urology 1993; 42: 559-562
• 17 Joerger M, Warzinek T, Klaeser B. et al. Major tumor regression after paclitaxel and carboplatin polychemotherapy in a patient with advanced penile cancer. Urology 2004; 63: 778-780
• 18 Houédé N, Dupuy L, Fléchon A. et al. Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma. BJU Int 2016; 117: 444-449
• 19 Skeel RT, Huang J, Manola J. et al. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest 2003; 21: 41-46
• 20 Haas GP, Blumenstein BA, Gagliano RG. et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol 1999; 161: 1823-1825
• 21 Corral DA, Sella A, Pettaway CA. et al. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol 1998; 160: 1770-1774
• 22 Hakenberg OW, Nippgen JBW, Froehner M. et al. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int 2006; 98: 1225-1227
• 23 Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol 1988; 27: 823-824
• 24 Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol 2009; 55: 546-551
• 25 Hakenberg OW, Compérat EM, Minhas S. et al. EAU guidelines on penile cancer: 2014 update. Eur Urol 2015; 67: 142-150
• 26 Nicholson S, Hall E, Harland SJ. et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer 2013; 109: 2554-2559
• 27 Bermejo C, Busby JE, Spiess PE. et al. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol 2007; 177: 1335-1338
• 28 Sitompul AP, Prapiska FF, Warli SM. Evaluation of Paclitaxel, Ifosfamide, and Cisplatin (TIP) Regimen on Penile Cancer in Adam Malik Medan: A Single Center 2 Years of Experience. Open Access Maced J Med Sci 2019; 7: 1148-1152
• 29 Clark PE, Spiess PE, Agarwal N. et al. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2013; 11: 594-615
• 30 Yuan Z, Naghavi AO, Tang D. et al. The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer. World J Urol 2018; 36: 1431-1440
• 31 Chipollini J, Necchi A, Spiess PE. Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention. Eur Urol 2018; 74: 241-242
• 32 Correa AF, Handorf E, Joshi SS. et al. Differences in Survival Associated with Performance of Lymph Node Dissection in Patients with Invasive Penile Cancer: Results from the National Cancer Database. J Urol 2018; 199: 1238-1244
• 33 Joshi SS, Handorf E, Strauss D. et al. Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis. JAMA Oncol 2018; 4: 643-649
• 34 Ulvskog E, Drevin L, Persson EK. et al. Oncological therapy to Swedish men with metastatic penile cancer 2000–2015. Acta Oncol 2021; 60: 42-49
• 35 Mistretta FA, Cyr S-J, Palumbo C. et al. Adherence to Guideline Recommendations for Perioperative Chemotherapy in Patients with pN2–3 M0 Squamous Cell Carcinoma of the Penis: Temporal Trends and Survival Outcomes. Clin Oncol (R Coll Radiol) 2020; 32: e93-e101
• 36 Pagliaro LC, Williams DL, Daliani D. et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010; 28: 3851-3857
• 37 Dickstein RJ, Munsell MF, Pagliaro LC. et al. Prognostic factors influencing survival from regionally advanced squamous cell carcinoma of the penis after preoperative chemotherapy. BJU Int 2016; 117: 118-125
• 38 Xu J, Li G, Zhu SM. et al. Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis. BMC Cancer 2019; 19: 625
• 39 Leijte JAP, Kerst JM, Bais E. et al. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol 2007; 52: 488-494
• 40 Necchi A, Pond GR, Raggi D. et al. Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. Clin Genitourin Cancer 2017; 15: 548-555.e3
• 41 Necchi A, Lo Vullo S, Mariani L. et al. Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. Urol Oncol 2019; 37: 531.e7-531.e15
• 42 Zou B, Han Z, Wang Z. et al. Neoadjuvant therapy combined with a BMP regimen for treating penile cancer patients with lymph node metastasis: a retrospective study in China. J Cancer Res Clin Oncol 2014; 140: 1733-1738
• 43 Azizi M, Aydin AM, Hajiran A. et al. Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. J Urol 2020; 203: 1147-1155
• 44 Pizzocaro G, Piva L, Nicolai N. Trattamento delle metastasi linfonodali da carcinoma spinocellulare del pene: l'esperienza dell'Istituto Nazionale tumori di Milano. Arch Ital Urol Androl 1996; 68: 169-172
• 45 Noronha V, Patil V, Ostwal V. et al. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urol Ann 2012; 4: 150-153
• 46 Nicolai N, Sangalli LM, Necchi A. et al. A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. Clin Genitourin Cancer 2016; 14: 323-330
• 47 Necchi A, Lo Vullo S, Nicolai N. et al. Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. Clin Genitourin Cancer 2016; 14: 518-523
• 48 Sharma P, Djajadiningrat R, Zargar-Shoshtari K. et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol 2015; 33: 496.e17-496.e23
• 49 Chen W-K, Wu Z-G. Adding radiotherapy based on chemotherapy can improve cancer-specific survival in N3 penile cancer: a SEER-based study. Transl Androl Urol 2020; 9: 2587-2595
• 50 Jakobsen JK, Alslev L, Ipsen P. et al. DaPeCa-3: promising results of sentinel node biopsy combined with (18) F-fluorodeoxyglucose positron emission tomography/computed tomography in clinically lymph node-negative patients with penile cancer – a national study from Denmark. BJU Int 2016; 118: 102-111
• 51 Jaipuria J, Kohli T, Venkatasubramaniyan M. et al. Adjuvant radiation compares favorably to chemotherapy in patients with carcinoma penis and nodal positivity restricted to groin. Urol Oncol 2020; 38: 641.e9-641.e18
• 52 Li Z-S, Li X-Y, Wang B. et al. Radiotherapy plus chemotherapy versus chemotherapy alone in penile cancer patients with extracapsular nodal extension after inguinal lymph node surgery: a multi-institutional study. World J Urol 2021; 39: 113-119
• 53 Ottenhof SR, de Vries HM, Doodeman B. et al. A prospective study of chemoradiotherapy as primary treatment in patients with locoregionally advanced penile carcinoma. Int J Radiat Oncol Biol Phys 2023;
• 54 Di Lorenzo G, Cartenì G, Autorino R. et al. Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. Anticancer Drugs 2009; 20: 277-280
• 55 Di Lorenzo G, Federico P, Buonerba C. et al. Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study. Eur Urol 2011; 60: 1280-1284
• 56 Pickering LM, Tovey H, Elliott T. et al. VinCaP: a phase II trial of vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis (CRUK/12/021). J Clin Oncol 2018; 36: 4514-4515
• 57 Challapalli A, Pearson S, Mitra AV. et al. A phase II trial of cabazitaxel as second line chemotherapy in relapsed locally advanced and/or metastatic carcinoma of the penis. J Int Med Res 2019; 47: 4664-4672
• 58 Wang J, Pettaway CA, Pagliaro LC. Treatment for Metastatic Penile Cancer After First-line Chemotherapy Failure: Analysis of Response and Survival Outcomes. Urology 2015; 85: 1104-1110
• 59 Montella M, Sabetta R, Ronchi A. et al. Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability. Front Med (Lausanne) 2022; 9: 874213
• 60 Ottenhof SR, Djajadiningrat RS, Jong J de. et al. Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status. J Urol 2017; 197: 690-697
• 61 Deng C, Li Z, Guo S. et al. Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. Oncoimmunology 2017; 6: e1269047
• 62 Su X, Zhang J, Fu C. et al. Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review. Onco Targets Ther 2020; 13: 3319-3324
• 63 Denis C, Sakalihasan S, Frères P. et al. Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer. Case reports in oncology 2021; 14: 972-976
• 64 Brown A, Ma Y, Danenberg K. et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology 2014; 83: 159-165
• 65 Chahoud J, Skelton WP, Spiess PE. et al. Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab. Front Oncol 2020; 10: 615298
• 66 Chen HX, Lin C-C, Lin C-H. et al. Combination of Durvalumab and Chemotherapy to Potentially Convert Unresectable Stage IV Penile Squamous Cell Carcinoma to Resectable Disease: A Case Report. Curr Oncol 2022; 30: 326-332
• 67 Du Y, Zhang X, Zhang Y. et al. PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report. Hum Vaccin Immunother 2022; 18: 2121122
• 68 Li N, Xu T, Zhou Z. et al. Immunotherapy Combined With Chemotherapy for Postoperative Recurrent Penile Squamous Cell Carcinoma: A Case Report and Literature Review. Front Oncol 2022; 12: 837547
• 69 Hu L, Shan X, Han D. et al. Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report. Onco Targets Ther 2021; 14: 4891-4896
• 70 Trafalis DT, Alifieris CE, Kalantzis A. et al. Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma. J Immunother 2018; 41: 300-305
• 71 Yan R, Ma H, Jiang L. et al. First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer. BJU Int 2023; 131: 198-207
• 72 Di Lorenzo G, Perdonà S, Buonerba C. et al. Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study. J Transl Med 2013; 11: 161
• 73 Huang XY, Kubota Y, Nakada T. et al. Intra-arterial infusion chemotherapy for penile carcinoma with deep inguinal lymph node metastasis. Urol Int 1999; 62: 245-248
• 74 Carthon BC, Ng CS, Pettaway CA. et al. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 2014; 113: 871-877
• 75 Necchi A, Lo Vullo S, Perrone F. et al. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. BJU Int 2018; 121: 348-356
• 76 Zhu Y, Li H, Yao X-D. et al. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int 2010; 85: 334-340